

Please refer to the **Drug Interactions** section of the Adult Guidelines for more detailed discussions.

Table 16b. Interactions between NNRTIs, Maraviroc, and PIs

Drug Affected	Delavirdine	Efavirenz	Etravirine	Nevirapine	Maraviroc
<i>Atazanavir (ATV)</i>	No data.	Levels: With unboosted ATV, ATV AUC ↓ 74%. EFV no change. ATV 300 + RTV 100mg QD with food - ATV concentrations similar to unboosted ATV Dose: in treatment-naïve patients, ATV 400mg + RTV 100mg; EFV dose = standard. Do not coadminister in treatment-experienced patients.	Levels: With unboosted ATV, ETR AUC, Cmax and Cmin ↑ 50%, 47% and 58%, respectively ATV AUC ↓ 17%, Cmin ↓ 47% With ATV/RTV, ETR AUC, Cmax and Cmin ↑ approx 30%: ATV AUC ↓ 14% and Cmin ↓ 38% Do not coadminister with unboosted ATV or ATV/RTV	Levels: ↓ ATV, ↑ NVP Coadministration of NVP is not recommended with ATV ± RTV.	Levels: With unboosted ATV, MVC AUC ↑ 3.6x. With ATV/r, MVC AUC ↑ 5x. Dose: With unboosted ATV or ATV/r, 150mg BID.
Darunavir (DRV)	No data.	Levels: DRV AUC and Cmin ↓ 13% and 31%, respectively. EFV AUC and Cmin ↑ 21% and 17%, respectively. Dose: Clinical significance unknown. Use standard doses and monitor closely. Consider monitoring levels.	Levels: ETR AUC ↓ 37% Cmin ↓ 49% DRV no change Dose: Standard for ETR and DRV. Despite decrease in ETR, safety and efficacy established with this combination	Levels: NVP AUC and Cmin ↑ 27% and 47%, respectively. DRV unchanged.† Dose: Standard.	Levels: With DRV/r, MVC AUC ↑ 4x. Dose: 150mg BID.
<i>Delavirdine (DLV)</i>	•	no data	•	•	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
<i>Efavirenz (EFV)</i>	no data	•	Potential for ↓ ETR concentration. Do not coadminister	•	Levels: MVC AUC ↓ 45%. Dose: 600mg BID.
<i>EFV + LPV/r or SQV/r</i>	•	•	•	•	Levels: MVC AUC ↑ 2.5–5x. Dose: 150mg BID.
<i>Etravirine (ETR)</i>	•	•	•	•	Levels: MVC AUC ↓ 53%, Cmax ↓ 60% Dose: 600mg BID
<i>ETR + DRV/r</i>	•	•	•	•	Levels: MVC AUC ↑ 210%, Cmax ↑ 77% Dose: 150mg BID
<i>Fosamprenavir (FPV)</i>	Levels: Presumably, similar PK effects as APV: APV AUC ↑ 130%, and DLV AUC ↓ 61%. Dose: Coadministration not recommended.	Levels: APV Cmin ↓ 36% (when dosed at 1,400mg QD with 200mg RTV). Dose: FPV 1,400mg + RTV 300mg QD; or FPV 700mg + RTV 100mg BID.	Levels: APV AUC ↑ 69%, Cmin ↑ 77% Dose: Do not coadminister with boosted or unboosted FPV	No data.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID
<i>Indinavir (IDV)</i>	Levels: IDV ↑ >40%; DLV- No effect. Dose: IDV 600mg q8h. DLV standard.	Levels: IDV ↓ 31%. Dose: IDV 1,000mg q8h; consider IDV/RTV. EFV standard.	Dose: No data. Do not coadminister	Levels: IDV ↓ 28%; NVP no effect. Dose: IDV 1,000mg q8h, or consider IDV/RTV. NVP standard.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
Lopinavir/ Ritonavir (LPV/r)	Levels: LPV levels expected to increase. Dose: Insufficient data.	Levels: With LPV/r tablets 600/150mg BID + EFV 600mg QD, LPV Cmin and AUC ↑ 35% and 36%, respectively. No formal study of LPV/r tablets 400/100mg BID + EFV. EFV no change. Dose: LPV/r tablets 600/150mg BID, when used in with EFV in tx-experienced patients. EFV dose - standard.	Levels: ETR AUC ↑ 17% Cmin ↑ 23%; LPV AUC ↓ 20%, Cmin ↓ 8% Dose: standard for ETR and LPV/RTV The amount of safety data at ↑ ETR exposures is limited, therefore, use with caution	Levels: With LPV/r capsules, LPV Cmin dec. 55%. Dose: LPV/r tablets 600/150mg BID, when used in combination with NVP in tx-experienced patients. NVP standard.	Levels: MVC AUC ↑ 4x. Dose: 150mg BID.
<i>Nelfinavir (NFV)</i>	Levels: NFV ↑ 2 times. DLV ↓ 50%. Dose: No data.	Levels: NFV ↑ 20%. Dose: Standard.	Dose: no data. Do not coadminister	Levels: NFV ↑ 10%. NVP no effect. Dose: Standard.	Levels: Unknown, possibly ↑ MVC conc. Dose: 150mg BID.
<i>Nevirapine (NVP)</i>	No data.	Levels: NVP-no effect. EFV AUC ↓ 22%.	Potential for ↓ ETR concentration, Do not coadminister	•	Levels: No significant change. Dose: 300mg BID if use without PI 150mg BID – if used with PI (except TPV/r).
<i>Ritonavir (RTV)</i>	Levels: RTV ↑ 70%. DLV no effect. Dose: Appropriate doses not established.	Levels: RTV ↑ 18%. EFV ↑ 21%. Dose: Standard.	Dose: No data. Do not coadminister ETR and RTV 600mg	Levels: RTV ↓ 11%. NVP no effect. Dose: Standard.	Levels: With RTV 100 mg BID, MVC AUC ↑ 2.6x. Dose: 150mg BID.

Please refer to the **Drug Interactions** section of the Adult Guidelines for more detailed discussions.

<p>Saquinavir (SQV)</p>	<p><u>Levels:</u> SQV[‡] ↑ 5 times; DLV no effect. <u>Dose:</u> SQV/RTV 1,000mg/100mg BID.</p>	<p><u>Levels:</u> SQV[‡] ↓ 62%. EFV ↓ 12%. <u>Dose:</u> SQV/RTV 1000mg/100mg BID.</p>	<p><u>Level:</u> ETR AUC ↓ 33% Cmin ↓ 29% SQV unchanged <u>Dose:</u> SQV/RTV 1000/100mg BID. ETR reduced exposures similar to ETR reduced exposures with DRV/RTV; therefore no dose adjustment</p>	<p><u>Levels:</u> SQV ↓ 25%. NVP no effect. <u>Dose:</u> SQV/RTV 1,000mg/100mg BID.</p>	<p><u>Levels:</u> With SQV/r, MVC AUC ↑ 9.8x. <u>Dose:</u> 150mg BID.</p>
<p>Tipranavir (TPV)</p>	<p>No data.</p>	<p><u>Levels:</u> With TPV/r 500/100mg BID, TPV AUC and Cmin ↓ 31% and 42%, respectively. EFV unchanged. With TPV/r 750/200mg BID, TPV PK unchanged. <u>Dose:</u> No dose adjustments necessary.</p>	<p><u>Level:</u> ETR AUC ↓ 76%, Cmin ↓ 82%; TPV AUC ↑ 18%, Cmin ↑ 24% <u>Dose:</u> Do not coadminister</p>	<p><u>Levels:</u> No data on the effect of NVP on TPV/r PK. NVP PK unchanged.^a</p>	<p><u>Levels:</u> With TPV/r, no significant change. <u>Dose:</u> 300mg BID.</p>

‡ Study conducted with Inivirase.

† Based on between-study comparison.

^a Study conducted with TPV/r dose(s) other than FDA-approved dose of 500/200mg BID.